Trial Profile
A Multicenter, Observational, Retrospective Study Investigating the Effectiveness and Safety of Nivolumab in Non-Small Cell Lung Cancer (NSCLC) Patients in Real Clinical Practice
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 04 Feb 2019
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 22 Dec 2018 Results assessing the effectiveness, safety and economic cost of nivolumab in real-world clinical practice published in the International Journal of Clinical Pharmacy
- 18 Jun 2018 New trial record
- 05 Jun 2018 Results presented at the 54th Annual Meeting of the American Society of Clinical Oncology.